Cargando…

Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy

Although the incidence of hepatocellular carcinoma (HCC) occurring after hepatitis C virus (HCV) eradication has decreased, there are still reports of hepatocarcinogenesis. The present study investigated the histological changes of non-cancerous liver tissue obtained prior to interferon (IFN) therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaguchi, Toshihiro, Ide, Tatsuya, Kondo, Reiichiro, Nomura, Yoriko, Arinaga-Hino, Teruko, Kuwahara, Reiichiro, Amano, Keisuke, Sano, Tomoya, Akiba, Jun, Ohshima, Koichi, Yano, Hirohisa, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781808/
https://www.ncbi.nlm.nih.gov/pubmed/31616517
http://dx.doi.org/10.3892/etm.2019.8024
_version_ 1783457445934268416
author Kawaguchi, Toshihiro
Ide, Tatsuya
Kondo, Reiichiro
Nomura, Yoriko
Arinaga-Hino, Teruko
Kuwahara, Reiichiro
Amano, Keisuke
Sano, Tomoya
Akiba, Jun
Ohshima, Koichi
Yano, Hirohisa
Torimura, Takuji
author_facet Kawaguchi, Toshihiro
Ide, Tatsuya
Kondo, Reiichiro
Nomura, Yoriko
Arinaga-Hino, Teruko
Kuwahara, Reiichiro
Amano, Keisuke
Sano, Tomoya
Akiba, Jun
Ohshima, Koichi
Yano, Hirohisa
Torimura, Takuji
author_sort Kawaguchi, Toshihiro
collection PubMed
description Although the incidence of hepatocellular carcinoma (HCC) occurring after hepatitis C virus (HCV) eradication has decreased, there are still reports of hepatocarcinogenesis. The present study investigated the histological changes of non-cancerous liver tissue obtained prior to interferon (IFN) therapy and after HCC development. A total of 669 HCV-infected Japanese patients who achieved sustained virological response (SVR) by IFN-based therapy were retrospectively enrolled. Of these, the present study investigated 18 patients who developed HCC after IFN-based SVR. Specimens from 9 of 18 patients were available for histological comparisons prior to IFN therapy and following HCC development. Of these 9 patients, the specimens of 5 individuals were compared via immunohistochemical staining [CD3, CD4, CD8, CD20, forkhead box P3 (FOXP3), transforming growth factor-β1 and granzyme B]. The current study included 6 control patients with HCV-associated chronic liver disease who subsequently developed HCC (non-SVR-HCC group). Mann-Whitney and Wilcoxon tests were used to compare groups. Bonferroni correction was used for multiple comparisons. P<0.05 was used as a critical P-value, and following Bonferroni's correction, P<0.017 was considered to indicate a statistically significant difference. In the 9 patients examined, continuous inflammation and fibrosis were observed after HCC development. There was also a significant decrease in the positive rate of FOXP3 in all 5 patients at the time of HCC development compared with that prior to IFN therapy (P=0.0084). Additionally, there was a significant difference in the positive rate of FOXP3 between the 5 patients after HCC development and the control individuals (P=0.0022). In patients who developed HCC after IFN-based SVR, the frequency of FOXP3 decreased, but inflammation and fibrosis remained. The extent of the reduction of FOXP3 differed in patients who developed HCC in the presence of HCV. Inflammation and fibrosis remained for a long duration after SVR, which may be associated with hepatocarcinogenesis.
format Online
Article
Text
id pubmed-6781808
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-67818082019-10-15 Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy Kawaguchi, Toshihiro Ide, Tatsuya Kondo, Reiichiro Nomura, Yoriko Arinaga-Hino, Teruko Kuwahara, Reiichiro Amano, Keisuke Sano, Tomoya Akiba, Jun Ohshima, Koichi Yano, Hirohisa Torimura, Takuji Exp Ther Med Articles Although the incidence of hepatocellular carcinoma (HCC) occurring after hepatitis C virus (HCV) eradication has decreased, there are still reports of hepatocarcinogenesis. The present study investigated the histological changes of non-cancerous liver tissue obtained prior to interferon (IFN) therapy and after HCC development. A total of 669 HCV-infected Japanese patients who achieved sustained virological response (SVR) by IFN-based therapy were retrospectively enrolled. Of these, the present study investigated 18 patients who developed HCC after IFN-based SVR. Specimens from 9 of 18 patients were available for histological comparisons prior to IFN therapy and following HCC development. Of these 9 patients, the specimens of 5 individuals were compared via immunohistochemical staining [CD3, CD4, CD8, CD20, forkhead box P3 (FOXP3), transforming growth factor-β1 and granzyme B]. The current study included 6 control patients with HCV-associated chronic liver disease who subsequently developed HCC (non-SVR-HCC group). Mann-Whitney and Wilcoxon tests were used to compare groups. Bonferroni correction was used for multiple comparisons. P<0.05 was used as a critical P-value, and following Bonferroni's correction, P<0.017 was considered to indicate a statistically significant difference. In the 9 patients examined, continuous inflammation and fibrosis were observed after HCC development. There was also a significant decrease in the positive rate of FOXP3 in all 5 patients at the time of HCC development compared with that prior to IFN therapy (P=0.0084). Additionally, there was a significant difference in the positive rate of FOXP3 between the 5 patients after HCC development and the control individuals (P=0.0022). In patients who developed HCC after IFN-based SVR, the frequency of FOXP3 decreased, but inflammation and fibrosis remained. The extent of the reduction of FOXP3 differed in patients who developed HCC in the presence of HCV. Inflammation and fibrosis remained for a long duration after SVR, which may be associated with hepatocarcinogenesis. D.A. Spandidos 2019-11 2019-09-18 /pmc/articles/PMC6781808/ /pubmed/31616517 http://dx.doi.org/10.3892/etm.2019.8024 Text en Copyright: © Kawaguchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kawaguchi, Toshihiro
Ide, Tatsuya
Kondo, Reiichiro
Nomura, Yoriko
Arinaga-Hino, Teruko
Kuwahara, Reiichiro
Amano, Keisuke
Sano, Tomoya
Akiba, Jun
Ohshima, Koichi
Yano, Hirohisa
Torimura, Takuji
Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy
title Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy
title_full Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy
title_fullStr Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy
title_full_unstemmed Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy
title_short Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy
title_sort histological changes in patients who developed hepatocellular carcinoma after hepatitis c virus eradication by interferon-based therapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781808/
https://www.ncbi.nlm.nih.gov/pubmed/31616517
http://dx.doi.org/10.3892/etm.2019.8024
work_keys_str_mv AT kawaguchitoshihiro histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT idetatsuya histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT kondoreiichiro histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT nomurayoriko histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT arinagahinoteruko histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT kuwaharareiichiro histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT amanokeisuke histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT sanotomoya histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT akibajun histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT ohshimakoichi histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT yanohirohisa histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy
AT torimuratakuji histologicalchangesinpatientswhodevelopedhepatocellularcarcinomaafterhepatitiscviruseradicationbyinterferonbasedtherapy